All
FDA Grants Priority Review to Revlimid Plus Rituxan for Indolent Non-Hodgkin Lymphoma
February 27th 2019The Food and Drug Administration granted a priority review to Revlimid (lenalidomide) plus Rituxan (rituximab) for the treatment of patients with previously treated follicular lymphoma and marginal zone lymphoma.
Topline Results Support Quicker, Convenient Administration of Darzalex in Myeloma Therapy
February 27th 2019Outcomes associated with subcutaneous injections of Darzalex (daratumumab) appeared similar to IV administration in patients with relapsed or refractory myeloma, according to the phase 3 COLUMBA trial.
The Administration's Drug Rebate Proposal: An Opportunity to Put Patients First
February 26th 2019Of all the health care regulations coming out of the current administration, the recent drug rebate proposal presents a new opportunity to significantly lower out-of-pocket prescription drug costs for Medicare patients. But like most things in health care, there is more complexity to the administration’s proposed changes to pharmaceutical company rebates than initially meets the eye.
FDA Grants Priority Review to Tibsovo for Acute Myeloid Leukemia Subgroup
February 20th 2019The Food and Drug Administration granted a priority review to Tibsovo (ivosidenib) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who are not eligible for standard therapy.
FGFR3 Inhibitor Shows Promise in Advanced Bladder Cancer
February 20th 2019Vofatamab (B-701) may be safe and effective for patients with locally advanced or metastatic bladder cancer with an FGFR3 mutation who have relapsed after, or are refractory to, at least one prior line of chemotherapy, according to preliminary findings.
FDA Grants Priority Review to Antibody Drug Conjugate for Diffuse Large B-Cell Lymphoma
February 19th 2019The Food and Drug Administration granted a priority review to polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).